(Total Views: 267)
Posted On: 04/20/2021 4:25:16 PM
Post# of 14
NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming article in a peer-reviewed journal. The company also announced that it has received notification from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with a Nasdaq Listing Rule requiring filing an annual report for fiscal year 2020. The notification letter has no immediate impact on the listing or trading of ATNF stock on the Nasdaq market. The company noted that it is reviewing the SEC statement; company auditors are also in the process auditing ATNF financial statements to complete the annual report as soon as practical. Regarding the phase 2b disease trial data, 180 Life Sciences CEO stated the following: “Despite the challenges posed by the COVID-19 pandemic and shut down of clinical sites across Europe due to government restrictions, we are fortunate to have had our investigators with the help of additional support from the Wellcome Trust, complete the collection of data. The data is being reviewed and validated, which is not an easy task under current conditions. The analysis will be according to the previously agreed Statistical Analysis Plan. We remain on track to announce a top-line data read out from this trial in Q4 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming article in a peer-reviewed journal. The company also announced that it has received notification from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with a Nasdaq Listing Rule requiring filing an annual report for fiscal year 2020. The notification letter has no immediate impact on the listing or trading of ATNF stock on the Nasdaq market. The company noted that it is reviewing the SEC statement; company auditors are also in the process auditing ATNF financial statements to complete the annual report as soon as practical. Regarding the phase 2b disease trial data, 180 Life Sciences CEO stated the following: “Despite the challenges posed by the COVID-19 pandemic and shut down of clinical sites across Europe due to government restrictions, we are fortunate to have had our investigators with the help of additional support from the Wellcome Trust, complete the collection of data. The data is being reviewed and validated, which is not an easy task under current conditions. The analysis will be according to the previously agreed Statistical Analysis Plan. We remain on track to announce a top-line data read out from this trial in Q4 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
